The meeting is over, and the final tally is not what the first day suggested. By the close of Friday afternoon, the FDA's Pharmacy Compounding Advisory Committee had recommended adding six of the seven peptides it reviewed to the 503A Bulks List, and had voted against one.
Emideltide, also known as delta sleep-inducing peptide or DSIP, failed on a 6 to 7 vote with one abstention. It had been proposed for insomnia, narcotic dependence, and opioid withdrawal. Epitalon cleared 7 to 5 with one abstention for insomnia. Semax cleared 8 to 5 for cerebral ischemia, migraine, and trigeminal neuralgia.
